A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The study is to explore the the reasonable dosage and to evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in combination with Serplulimab (anti-PD-1 humanized monoclonal antibody injection) in patients with advanced lung cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 18 do 75 lat
- •Potwierdzone zaawansowane stadium raka płuca (III lub IV) bez możliwości standardowego leczenia operacyjnego
- •Wcześniejsze leczenie chemioterapią i lekami immunoterapii
- •Co najmniej jeden widoczny nowotwór zmierzalny w badaniach obrazowych
- •Dostępna próbka tkanki nowotworu do badań lub gotowość do biopsji
- •Przerwa co najmniej 3 tygodnie od poprzedniego leczenia
- •Powrót efektów ubocznych z poprzedniego leczenia do łagodnego stopnia lub niższego
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- July 21, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (10)
The Second Hospital of Anhui Medical University
Hefei, China
Fujian Cancer Hospital
Fu'zhou, China
Cancer Hospital of Guangzhou Medical University
Guangzhou, China
The People's Hospital of Guangxi Zhuangzu Autonomous Region
Nanning, China
Cangzhou People's Hospital
Cangzhou, China
Harbin Medical University Cancer Hospital
Harbin, China
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, China
Hubei Cancer Hospital
Wuha, China
Shanghai Chest Hospital
Shanghai, China
THE Affiliated Hospital of Xuzhou Medical University
Xuzhou, China
Trial contact
Yongqing Lin
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.